Astrazeneca (AZN) Net Margin (2009 - 2026)
Astrazeneca (AZN) posted quarterly Net Margin of 4000.0% for Q1 2026, down 142838.0% year-over-year from N/an in Q1 2025, and down 91.34% on a QoQ basis from 46166.67% in Q4 2025.
Astrazeneca (AZN) Net Margin (2009 - 2026) Analysis & Trends
Astrazeneca (AZN) has reported Net Margin for 18 consecutive years, with 4000.0% the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Margin fell 142838.0% year-over-year to 4000.0%; the TTM figure through Mar 2026 stood at 11746.08% (up 1068505.0% YoY), while the FY2025 annual figure was 17.41%, down 74478.0% from the prior year.
- Net Margin came in at 4000.0% for Q1 2026 at Astrazeneca, down from 46166.67% in the prior quarter.
- The five-year high for Net Margin was 48250.0% in Q2 2024, with the low at 12400.0% in Q2 2022.
- Average Net Margin over 5 years is 10709.99%, with a median of 4000.0% recorded in 2026.
- Across the five-year window, Net Margin slumped 1240000 bps in 2022 and surged 4730803 bps in 2024, its largest moves.
- Year by year, Net Margin stood at 1083.54% in 2022, then slumped by 41 bps to 642.96% in 2023, then sank by 71 bps to 184.05% in 2024, then surged by 24984 bps to 46166.67% in 2025, then slumped by 91 bps to 4000.0% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 4000.0%, 46166.67%, and 23409.09% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 37.36% |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 21.76% |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 4.65% |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 329.02% |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -25.84% |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 21.11% |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 29.04% |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -0.56% |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 12.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 329.02% |
| Dec 31, 2025 | 19.05% |
| Sep 30, 2025 | 17.93% |
| Jun 30, 2025 | 324.17% |
| Mar 31, 2025 | 31.20% |
| Dec 31, 2024 | 11.23% |
| Sep 30, 2024 | 314.51% |
| Jun 30, 2024 | 15.50% |
| Mar 31, 2024 | 17.89% |
| Dec 31, 2023 | 15.73% |
| Sep 30, 2023 | 337.60% |
| Jun 30, 2023 | 16.71% |
| Mar 31, 2023 | 20.64% |
| Dec 31, 2022 | 15.28% |
| Sep 30, 2022 | 319.92% |
| Jun 30, 2022 | -3.50% |
| Mar 31, 2022 | 3.56% |
| Dec 31, 2021 | -6.50% |
| Sep 30, 2021 | -20.35% |
| Jun 30, 2021 | 0.00% |